LABVANTAGE Signs Global Contract with Prominent Diagnostic Organization
News Mar 19, 2012
LABVANTAGE announced that its laboratory information management system (LIMS) and electronic laboratory notebook (ELN) were selected by a world-class provider that specializes in in vitro infectious disease diagnostics, including designing, developing, manufacturing and marketing reagents and automated instruments for medical analyses and cosmetics, and product quality control in the agro-food and pharmaceutical industries. The initial contract in excess of $3M will span global operations with numerous subsidiaries to harmonize processes and leverage the benefits of deploying a single, global LIMS across all laboratory sites. The harmonized configuration, testing, and compliance protocols to all sites worldwide will enable better decision-making and conformance while minimizing the impact to individual sites’ maintenance and support.
“We are very pleased that this prominent advocate for improving public health has chosen LABVANTAGE after its thorough global due diligence effort,” states Jeff Ferguson, LABVANTAGE Chief Executive Officer. “This significant commitment serves to further validate our strategy of increased investment in products and people that enable our customers to increase the pace of product development while decreasing their total cost of laboratory operations across all departments and locations.”
With over 6,000 employees worldwide and revenue in the billions, the organization will implement LABVANTAGE initially in its quality management laboratories and expand to include worldwide R&D sites in future phases. The LABVANTAGE system will initially interface with other applications, such as SAP, OpenText Corporations’s LiveLink ECM, Cognos BI, Sparta System’s Trackwise for training and quality management, and numerous laboratory instruments using the LABVANTAGE Connect instrument integration software.
Single-stranded Origami Technology Drives Drug Delivery Systems and Pharmaceutical Nanofactories ForwardNews
First nanotechnological approach enables the design and replication of complex single-stranded DNA and RNA origami with potential for drug delivery and nanofabrication.READ MORE
Leibniz Supercomputing Centre Introduces Plans for its Next-generation SuperMUC MachineNews
Leadership at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences and Humanities announced today that they have signed a contract with Intel and Lenovo to build SuperMUC-NG, the next generation of the centre's leading-edge supercomputers.READ MORE
New Computational Strategies Could Help Peptide Therapeutics DevelopmentNews
New computational strategies reported this week might help realize the promise of peptide-based drugs. Peptides are similar to protein molecules, but differ in their smaller size, structure and functions.READ MORE